CPX-351 Demonstrates Long-Term Survival Benefits in Patients With AML

April 23, 2021
Jorge E. Cortes, MD

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the 5-year overall survival (OS) results of CPX-351 (Vyxeos) versus 7+3 (cytarabine and anthracycline) in patients with newly diagnosed high-risk or secondary acute myeloid leukemia (AML).

Eighteen percent of patients who received CPX-351 were alive at 5 years compared with 8% who received 7+3. Cortes says there was clearly still a benefit long term and although the investigators would like to see higher OS rates, the doubling of survival in the CPX-351 arm was important.

The subgroup analyses showed that the benefits of CPX-351 were maintained across age groups on this phase 3 trial. The 3-year survival in the patients 60 to 69 years old, was 23% versus 14% for CPX-351 and 7+3, respectively. For patients 70 to 75 years old, there was an 18% 3-year OS rate for CPX-351 compared with 0% with 7+3. At 5 years, the OS was 20% in the younger population receiving CPX-351 and 12% for those receiving 7+3. For the older population, the survival rate at 5 years was 16% versus 0%, respectively. The benefit with CPX-351 was applicable to both age groups, according to Cortes.